What is claimed is:

1. A method of treating migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR$_5$ receptor antagonist or a pharmaceutically acceptable salt thereof.

2. A method of treating migraine comprising administering to a patient in need thereof a pharmaceutical composition comprising a selective iGluR$_5$ receptor antagonist in combination with one or more pharmaceutically acceptable carriers, diluents, or excipients.

3. The method according to Claim 1 wherein the selective iGluR$_5$ receptor antagonist is 3S, 4aR, 6S, 8aR-6-(((4-carboxy) phenyl) methyl) –1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a –decahydroisoquinoline-3-carboxylic acid.

4. The method according to Claim 1 wherein the selective iGluR$_5$ receptor antagonist is 3S, 4aR, 6S, 8aR-6-((((1H-Tetrazole-5-yl) methyl) oxy) methyl) – 1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylic acid.

5. The method according to Claim 1 wherein the selective iGluR$_5$ receptor antagonist is given by the formula



6. The method according to Claim 1 wherein the selective iGluR$_5$ receptor antagonist is a compound of the formula



wherein R^1 and R^2 are each independently H, C_1-C_{20} alkyl, C_2-C_6 alkenyl, C_1-C_6 alkylaryl, C_1-C_6 alkyl(C_3-C_{10})cycloalkyl, C_1-C_6 alkyl-N,N-C_1-C_6 dialkylamine, C_1-C_6 alkyl-pyrrolidine, C_1-C_6 alkyl-piperidine, C_1-C_6 alkyl-morpholine or a pharmaceutically acceptable salt thereof.

7. The method according to Claim 6 wherein the selective iGluR$_5$ receptor antagonist is selected from 3S, 4aR, 6S, 8aR Ethyl 6-(((2S)-2-(Ethoxycarbonyl)-4,4-difluoropyrrolidinyl)methyl)-1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylate, or 3S, 4aR, 6S, 8aR 6-(((2S)-2-(Carboxylic acid)-4,4-difluoropyrrolidinyl)methyl)-1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylic Acid

8. A method of treating dural protein extravasation comprising administering to a patient in need thereof an effective amount of a selective iGluR$_5$ receptor antagonist.

9. A method of treating migraine comprising administering to a patient in need thereof an effective amount of a compound, or combination thereof, which possesses the activity of a selective iGluR5 receptor antagonist.

10. The use of a selective iGluR$_5$ receptor antagonist for the manufacture of a medicament for treating migraine.

11. The use according to Claim 10 wherein the selective iGluR$_5$ receptor antagonist is 3S, 4aR, 6S, 8aR-6-(((4-carboxy) phenyl) methyl) –1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a – decahydroisoquinoline-3-carboxylic acid.

12. The use according to Claim 10 wherein the selective iGluR$_5$ receptor antagonist is 3S, 4aR, 6S, 8aR-6-((((1H-Tetrazole-5-yl) methyl) oxy) methyl) – 1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylic acid.

13. The use according to Claim 10 wherein the selective iGluR$_5$ receptor antagonist is given by the formula



14. The use according to Claim 10 wherein the selective iGluR$_5$ receptor antagonist is a compound of Formula I



wherein R^1 and R^2 are each independently H, C_1-C_{20} alkyl, C_2-C_6 alkenyl, C_1-C_6 alkylaryl, C_1-C_6 alkyl(C_3-C_{10})cycloalkyl, C_1-C_6 alkyl-N,N-C_1-C_6 dialkylamine, C_1-C_6 alkyl-pyrrolidine, C_1-C_6 alkyl-piperidine, or C_1-C_6 alkyl-morpholine; or a pharmaceutically acceptable salt thereof.

15. The use according to Claim 14 wherein the selective iGluR$_5$ receptor antagonist is selected from 3S, 4aR, 6S, 8aR Ethyl 6-(((2S)-2-(Ethoxycarbonyl)-4,4-difluoropyrrolidinyl)methyl)-1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylate, or 3S, 4aR, 6S, 8aR 6-(((2S)-2-(Carboxylic acid)-4,4-difluoropyrrolidinyl)methyl)-1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylic Acid

16. A compound of the formula



wherein R^1 and R^2 are each independently H, C_1-C_{20} alkyl, C_2-C_6 alkenyl, C_1-C_6 alkylaryl, C_1-C_6 alkyl(C_3-C_{10})cycloalkyl, C_1-C_6 alkyl-N,N-C_1-C_6 dialkylamine, C_1-C_6 alkyl-pyrrolidine, C_1-C_6 alkyl-piperidine, C_1-C_6 alkyl-morpholine or a pharmaceutically accepatable salt thereof.

17. A compound according to Claim 16 wherein R^1 and R^2 are each independently H or C_1-C_{20} alkyl.

18. A compound which is 3S, 4aR, 6S, 8aR Ethyl 6-(((2S)-2-(Ethoxycarbonyl)-4,4-difluoropyrrolidinyl)methyl)-1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylate, or a pharmaceutically acceptable salt thereof.

19. A compound which is 3S, 4aR, 6S, 8aR 6-(((2S)-2-(Carboxylic acid)-4,4-difluoropyrrolidinyl)methyl)-1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

20. A pharmaceutical composition which comprises a compound as claimed in Claim 16 in combination with one or more pharmaceutically acceptable carriers, diluents, or excipients.

21. A pharmaceutical composition for the treatment of migraine which comprises a selective $iGluR_5$ receptor antagonist in combination with a pharmaceutically acceptable carrier, diluent, or excipient.

22. A compound which is 3S, 4aR, 6S, 8aR Ethyl 6-(((2S)-2-(Ethoxycarbonyl)-4,4-difluoropyrrolidinyl)methyl)-1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylate•mandelate.